* Bio Path Holdings Inc BPTH.OQ BPTH.O is expected
to show no
change in quarterly revenue when it reports results on March
11.
* Refinitiv's mean analyst estimate for Bio Path Holdings
Inc is
for a loss of 32 cents per share. For the same quarter last
year, the company reported a loss of 57 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bio Path
Holdings
Inc is $12.5, above its last closing price of $3.25.
This summary was machine generated March 9 at 13:39 GMT. All
figures in US dollars unless otherwise stated